Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2010

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

(1) , (2) , (3, 4) , (5) , (1) , (3) , (3, 4) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (2) , (2) , (1) , (17) , (18) , (5) , (2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Christiane Pott
  • Function : Correspondent author
  • PersonId : 870838

Connectez-vous pour contacter l'auteur
Peter Dreger
Elizabeth Macintyre

Abstract

The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.
Fichier principal
Vignette du fichier
2009_pott_blood.pdf (268.16 Ko) Télécharger le fichier
Vignette du fichier
inserm-00481726_edited.pdf (638.29 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00481726 , version 1 (24-06-2010)

Identifiers

Cite

Christiane Pott, Eva Hoster, Marie-Hélène Delfau-Larue, Kheira Beldjord, Sebastian Böttcher, et al.. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma. Blood, 2010, 115 (16), pp.3215-23. ⟨10.1182/blood-2009-06-230250⟩. ⟨inserm-00481726⟩
755 View
1073 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More